The present disclosure generally relates to devices intended for removing acute blockages from blood vessels, and more particularly, to stentriever devices with membranes to direct fluid aspiration and enhance the stentriever's grip on an occlusive clot.
There are significant challenges associated with designing clot removal devices that can deliver high levels of performance. One challenge stems from the nature of the vasculature around an occlusive clot, which is often fragile and delicate. Neurovascular vessels, for example, are more fragile than similarly sized vessels in other parts of the body. Applying excessive tensile forces to these vessels could result in perforations and hemorrhage. Another challenge stems from the wide range of morphologies and consistencies of occlusive clots. Long strands of softer clot material may tend to lodge at bifurcations or trifurcations, resulting in multiple vessels being simultaneously occluded over significant lengths. More mature and organized clot material is likely to be less compressible than softer, fresher clot material, and under the action of blood pressure it may distend the compliant vessel in which the clot is lodged.
Stent-like clot retrievers, otherwise known as stentrievers, are being increasingly used to remove clots, as the devices show promise in dealing with some of the challenges described above. Stentrievers are self-expanding devices, similar in appearance to a stent attached to the end of a long shaft, which are advanced through a microcatheter and deployed across clot obstructions in order to trap and retrieve the clot. Many stentrievers rely on a pinning mechanisms to grab the clot by trapping the clot between the self-expanding, stent-like body and the vessel wall. Current stentrievers have a number of disadvantages that decrease the utility of the devices.
One disadvantage is that many stentrievers rely exclusively on an outward radial force (RF) to retain a grip on the clot. If the RF is too low the stentriever may lose its grip on the clot, but if the RF is too high the stentriever may damage the vessel wall and/or may require excessive force to withdraw the stentriever from the vessel. Stentrievers that apply sufficient RF to deal with all clot types may cause vessel trauma and serious patient injury, and stentrievers that apply low RF to remain atraumatic may not effectively handle all clot types.
Another disadvantage with current stentrievers is with the pinning mechanism itself. Stentrievers that rely exclusively on pinning clots against a vessel wall may not restrain the clot effectively when passing a branch vessel or when passing into a vessel that is larger than the fully expanded diameter of the stentriever. These and other disadvantages exist with previous stentriever devices. Accordingly, there is an ongoing need for an improved stentriever device that can improve grip on an occlusive clop without increasing the outward RF on the clot, thereby protecting the surrounding vasculature.
Examples presented herein include stentrievers with membranes to direct fluid aspiration and enhance the stentriever's grip on an occlusive clot. The stentriever design described herein can include a membrane cover on the proximal end which can be sized to form a seal with the tip of an intermediate catheter. Clot engagement sections and/or a distal engagement section of the stentriever can also include a full or partial membrane covering to control the direction of aspiration and/or areas where the aspiration applies suction to the thrombus or clot. The membranes can be used to direct the aspiration so as to pull the clot deeper into the clot engagement sections of the stentriever, thereby improving grip on the clot. The design can also increase the effectiveness of clot fragment protection for friable clots by providing pores and/or clot cells in a distal engagement section.
An example stentriever can include a shaft extending between a proximal end and a distal end. A first expandable clot engagement section can extend from the shaft. The stentriever can include a proximal flow channel that is positioned proximal to the first expandable clot engagement section. The proximal flow channel can include a membrane covering to direct an aspiration from the first expandable clot engagement section and through the proximal flow channel. The stentriever can comprise a collapsed configuration to be inserted into a microcatheter and include an expanded configuration for exerting an outward radial force on an occlusive clot.
The first expandable clot engagement section can include a first clot inlet to capture the clot. The first clot inlet can be positioned on the stentriever distal to the first expandable clot engagement section.
The proximal flow channel can include a collapsed configuration to be inserted into a microcatheter, and the proximal flow channel can include an expanded configuration to exert an outward radial force on an intermediate catheter. In the expanded configuration, the proximal flow membrane can engage with an inner surface of the intermediate catheter at a proximal seal area do direct aspiration flow.
The first expandable clot engagement section can include a first clot engagement membrane directing the aspiration into the first expandable clot engagement section.
The stentriever can include a second expandable clot engagement section that extends from the shaft. The second expandable clot engagement section can be positioned distal to the first expandable clot engagement section.
The second expandable clot engagement section can include a second clot engagement membrane to direct the aspiration into the second expandable clot engagement section.
The second expandable clot engagement section can include a second clot inlet to capture the clot. The second clot inlet can be positioned on the stentriever distal to the second expandable clot engagement section.
The stentriever can include an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section. The intermediate flow channel can direct the aspiration from the second expandable clot engagement section to the first expandable clot engagement section.
The stentriever can include a distal engagement section positioned distal to the first expandable clot engagement section. The distal engagement section can extend from the shaft. The distal engagement section can include a plurality of distal clot cells to capture clot fragments, such that the clot fragments do not pass distal to the stentriever.
The distal engagement section can include a distal membrane. The distal membrane can include distal pores that can constrict the flow of aspiration into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or second expandable clot engagement sections to further pull the clot into the engagement sections.
The first expandable clot engagement section can further include a first clot inlet capturing the clot. A distal membrane can constrict flow from the distal engagement section to the proximal flow channel to create a negative pressure at the first expandable clot engagement section, thereby pulling the clot into the first clot inlet.
An example system for removing a clot from a vessel can include a stentriever. The stentriever can include a shaft extending between a proximal end and a distal end. The stentriever can include a first expandable clot engagement section extending from the shaft. The stentriever can include a proximal flow channel positioned proximal to and adjacent the first expandable clot engagement section. The proximal flow channel can include a proximal flow membrane. The system can further include an intermediate catheter. The stentriever can have a collapsed configuration to be inserted into a microcatheter, and the stentriever can have an expanded configuration to expand in a vessel. In the expanded configuration, the proximal flow cannel can exert a radial force on the intermediate catheter, and the proximal flow membrane can seal against the inner surface of the intermediate catheter. The aspiration can be directed from the first expandable clot engagement section, through the proximal flow channel, and into the intermediate catheter.
The first expandable clot engagement section can include a first clot inlet to capture a clot within the vessel.
The first expandable clot engagement section can include a first clot engagement membrane. The first clot engagement membrane can direct an aspiration into the first expandable clot engagement section.
The stentriever can further include a second expandable clot engagement section extending from the shaft. The second expandable clot engagement section can be positioned distal to the first expandable clot engagement section. The second expandable clot engagement section can further include a second clot inlet for capturing the clot.
The stentriever can further include an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section. The intermediate flow channel can direct the aspiration from the second expandable clot engagement section to the first expandable clot engagement section.
The second expandable clot engagement section can include a second clot engagement membrane directing the aspiration into the second expandable clot engagement section.
The stentriever can include a distal engagement section positioned distal to the first expandable clot engagement section and extending from the shaft.
The distal engagement section can include a plurality of distal clot cells for capturing clot fragments.
The distal engagement section can include a distal membrane. The distal membrane can include distal pores that constrict flow of the aspiration into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or section expandable clot engagement sections to further pull the clot into the engagement sections.
The distal membrane can include distal flow aperture directing the aspiration into the distal engagement section. The distal flow aperture can be a partial opening in the distal engagement section that constricts a flow of the aspirate into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or section expandable clot engagement sections to further pull the clot into the engagement sections.
An example method for removing a clot from a vessel can include delivering a stentriever into the vessel and across the clot. The stentriever can include a shaft extending between a proximal end and a distal end. The stentriever can include an expandable clot engagement section extending from the shaft. The expandable clot engagement section can include a clot engagement membrane for directing a fluid into the expandable clot engagement section and a clot inlet. The stentriever can include a proximal flow channel positioned proximal to and adjacent the expandable clot engagement section. The proximal flow channel can include a proximal flow membrane. The proximal flow membrane can direct the fluid from the expandable clot engagement section and to the proximal flow channel. The method can include expanding the stentriever so that the expandable clot engagement section expands and exerts a radial force on the clot to engage the clot. The method can include advancing an intermediate catheter into the vessel and to the proximal flow channel. The proximal flow membrane can seal to an inner surface of the intermediate catheter. The method can include applying aspiration to the intermediate catheter such that a flow of the fluid is directed by the clot engagement membrane and into the proximal flow channel to capture the clot in the clot inlet. The method can include pulling the stentriever proximally to remove the clot from the vessel.
The stentriever can include a distal engagement section positioned distal to the expandable clot engagement section and extending from the shaft. The distal engagement section can include a distal membrane with a plurality of distal pores. The method can further include constricting, via the distal membrane, the flow of the fluid through the plurality of distal pores and into the distal engagement section. The constriction of the fluid flow can create a negative pressure to pull the clot into the clot inlet.
The distal engagement section can include a plurality of distal clot cells. The method can include preventing, via the plurality of distal clot cells, at least some clot fragments from passing distal to the stentriever.
The above and further aspects of this invention are further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation.
Aspects of the present invention relate to a stentriever that includes a full or partial membrane cover on the proximal end of the device that is sized so that the proximal section can form a seal with the tip of an intermediate catheter. The stentriever device can include one or more expandable clot engagement sections and/or a distal engagement section. The expandable clot engagement sections and the distal engagement section can also include a membrane covering to control the direction of aspirate, and thus the direction of suction upon a thrombus or clot. The direction of aspirate can act to pull a clot deeper into inlet windows (i.e., clot inlets) of the expandable clot engagement sections. The direction of aspirate and suction can improve clot grip, decrease dislodgement of a clot within the stentriever, and increase retention of the clot when the clot is pulled into the intermediate catheter, access or guide catheter, or access sheath. In some examples, the design can also increase the effectiveness of clot-fragment protection for friable clots by providing antegrade flow through the distal engagement section.
Turning to the figures,
The first expandable clot engagement section 102 can be made from a material capable of recovering its shape automatically once unsheathed into its expanded configuration. The material could be in many forms such as wire, strip, sheet, or tube. In some examples, the first expandable clot engagement section 102 can include, but is not limited to, Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a first expandable clot engagement section 102 can be made by heat setting the material to the expanded configuration.
In some examples, a stentriever 100 can include a first clot engagement membrane 104 attached to the first expandable clot engagement section 102. The first clot engagement membrane 104 can be a full or partial covering of the first expandable clot engagement section 102 to direct a suction and/or aspirate into the first expandable clot engagement section 102. The material for the first clot engagement membrane 104 can include silicon, polyurethane, polypropylene, polyethersulfone, and/or the like. In some examples, the material for the first clot engagement membrane 104 can be pliable such that the material can be opened as the first expandable clot engagement section 102 opens from a collapsed configuration to an expanded configuration.
A first expandable clot engagement section 102 can include a first clot inlet 106. A first clot inlet 106 can be an opening distal to the first expandable clot engagement section 102 that is not covered by a first clot engagement membrane 104 and provides an area for an occlusive clot to be pulled into the first expandable clot engagement section 102. As will be appreciated, the examples described herein provide a way to capture a clot without relying exclusively on the radial force applied by the expandable sections of the stentriever 100. As suction is applied to the stentriever 100, the clot can be directed along with the flow of aspirate into the first clot inlet 106 via the first clot engagement membrane 104, and continued suction can provide improved grip on the clot.
A stentriever 100 can include a proximal flow channel 108. The proximal flow channel 108 can be positioned proximal to the first expandable clot engagement section 102. The proximal flow channel 108 can have a collapsed configuration and an expanded configuration, similar to the first expandable clot engagement section 102 described above. It is contemplated that the diameter 109 of a proximal flow channel 108 in a collapsed configuration can, similar to the first expandable clot engagement section 102, be less than approximately 1.75 mm so as to fit within a microcatheter for delivery into the vessel.
The proximal flow channel 108 can be a braided tube, laser cut metallic tube, laser cut polymeric tube and/or the like. In some examples, the proximal flow channel 108 can include, but is not limited to, materials such as Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a proximal flow channel 108 can be made by heat setting the material to the expanded configuration.
The proximal flow channel 108 can include a proximal flow membrane 110. The proximal flow membrane 110 can cover an outer surface of the proximal flow channel 108 at a position proximal to the first expandable clot engagement section 102. The proximal flow membrane 110 can direct the flow of aspirate from the first expandable clot engagement section 102 and through the proximal flow channel 108. The flow of the aspirate through the proximal flow channel 108 can increase the suction around the first expandable clot engagement section 102 so as to pull a clot deeper into first clot inlet 106. The material for the proximal flow membrane 110 can be silicon, polyurethane, polypropylene, polyethersulfone, and/or the like. In some examples, the material for the proximal flow membrane 110 can be pliable such that the material can be opened as the proximal flow channel 108 opens from a collapsed configuration to an expanded configuration.
In some examples, the proximal flow channel 108 can be opened into its expanded configuration while deployed into the vessel. Once expanded, the proximal flow channel 108 can have a diameter 109 of approximately equal to the inner diameter of an intermediate or access catheter. For example, once deployed, an intermediate catheter can be advanced into position after the stentriever 100 is deployed within a clot. The intermediate catheter can be directed to the proximal flow channel 108. In some examples, the proximal flow membrane 110 can form a seal with the inner surface of the intermediate catheter. The seal can allow aspiration to be drawn from the first expandable clot engagement section 102, through the membrane-covered proximal flow channel 108, and into the intermediate catheter to further pull the clot into the first clot inlet 106. Intermediate catheters can have an inner diameter of approximately 0.040 inches to approximately 0.120 inches (approximately 1.0 mm to approximately 3.0 mm). Accordingly, it is contemplated that the diameter 109 of a proximal flow channel 108 in an expanded configuration can fall within those ranges.
The proximal flow channel 108 can have a length suitable for engaging with an intermediate catheter which has been forwarded to the vicinity of the clot. In another embodiment, the proximal flow channel can have sufficient length to engage with an intermediate or access catheter which has been parked in the Internal Carotid Artery. It is contemplated that the length of the proximal channel can have a range of approximately 2.0 mm to 100 mm.
A stentriever 100 can include a flexible shaft 112. The shaft 112 can act as a both a delivery mechanism to feed the stentriever 100 into the vessel and as a scaffold or frame for the additional features of the stentriever 100. The expandable clot engagement sections (e.g., first expandable clot engagement section 102) for example, can be connected to and extend from the shaft 112. The shaft can be made from a flexible material, including but not limited to metals and polymers, such that the stentriever 100 can bend as the device is deployed into a vessel.
A stentriever 100 can include a second expandable clot engagement section 114. The second expandable clot engagement section 114 can extend from the shaft 112, similar to the first expandable clot engagement section 102, and be positioned distal to the first expandable clot engagement section 102 on the shaft 112. The second expandable clot engagement section 114 can be similar in all aspects to the first expandable clot engagement section 102. Though the first expandable clot engagement section 102 and second expandable clot engagement section 114 can comprise identical materials and have identical dimension, nothing requires the two sections to be identical. The second expandable clot engagement section 114 can act as a second capturing device, wherein in an expanded configuration, the second expandable clot engagement section 114 can engage the clot within vessel by exerting a radial force upon the clot. Although
In some examples, a stentriever 100 can include a second clot engagement membrane 116 attached to the second expandable clot engagement section 114. The second clot engagement membrane 116 can be a full or partial covering of the second expandable clot engagement section 114 to direct a suction and/or aspirate into the second expandable clot engagement section 114. The material for the second clot engagement membrane 116 can be similar to the materials described above for the first clot engagement membrane 104.
A second expandable clot engagement section 114 can include a second clot inlet 118. A second clot inlet 118 can be an opening distal to the second expandable clot engagement section 114 that is not covered by a second clot engagement membrane 116 and provides an area for an occlusive clot to be pulled into the second expandable clot engagement section 114. By providing a first clot inlet 106 and a second clot inlet 118, the clot can be pulled, by providing aspiration to the proximal flow channel 108, into both clot inlets 106,118 for improved grip on the clot.
A shaft 112 of a stentriever 100 can include a distal tip 120. The distal tip 120 can include a rounded and/or smooth end so as to not perforate a wall of a vessel as the stentriever 100 is being deployed within the vessel. In some examples, the distal tip 120 can include radiopaque coil or marker disposed on or in the distal tip 120 for visibility under fluoroscopy. Additional radiopaque coils or markers can be added near the expandable clot engagement sections such that a physician can view the position of the device in relation to the occlusive clot under fluoroscopy.
A stentriever 100 can include a distal engagement section 202 positioned distal to the first expandable clot engagement section 102; when a stentriever 100 includes a second expandable clot engagement section 114, the distal engagement section 202 is distal to the second section. When a physician inserts the stentriever 100 into a vessel, the stentriever 100 can be passed beyond the clot such that the distal engagement section 202 is within the vessel distal to the clot. The distal engagement section 202 can have a collapsed configuration and an expanded configuration, and the dimensions of the distal engagement section 202 in the collapsed configuration and the expanded configuration can be similar to the dimensions described above for the first expandable clot engagement section 102. As will be described below, once expanded, the distal engagement section 202 can expand to fill the cross-sectional area of the vessel and constrict fluid flow through the distal engagement section 202. The materials that can be used for a distal engagement section 202 can include, but are not limited to, Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a distal engagement section 202 can be made by heat setting the material to the expanded configuration.
A distal engagement section 202 can include a distal membrane 204. The distal membrane 204 can be a partial membrane covering of the distal end of the distal engagement section 202. The material for the distal membrane 204 can be silicon, polyurethane, polypropylene, polyethersulfone, and/or the like.
The distal membrane 204 can include one or more distal pores 206. Distal pores 206 can be holes created in the distal membrane 204 to allow flow, albeit limited flow, through the distal membrane 204. The distal pores 206 can be laser cut, stamped, or perforated holes within the material of the distal membrane 204. At least a portion of the distal pores 206 can have a length of less than 500 micrometers from one side of the distal pore 206 to the other. In the case that the distal pores 206 are circular, the circular distal pores 206 can have a diameter of less than 500 micrometers. The length and/or diameter of the distal pores 206 can be altered so as to increase or decrease the amount of flow permitted through the distal pores 206. For example, distal pores 206 can constrict (i.e., partially limit but not necessarily completely restrict) flow of aspirate through the distal engagement section 202. When suction is applied to the proximal flow channel 108 via an intermediate catheter, the constricted flow through the distal pores 206 can create an area of negative pressure between the distal engagement section 202 and the first expandable clot engagement section 102. This negative pressure can increase the suction of the clot into the first clot inlet 106, thereby improving grip on the clot. When a stentriever 100 includes a second expandable clot engagement section 114, the negative pressure provided by the constricted flow can also further pull the clot into a second clot inlet 118.
In some examples, the distal pores 206 can also serve to prevent friable-clot fragments from passing distal to the stentriever 100. As described above, clots are oftentimes fragile and delicate. When a clot is being removed from a vessel, fragments of the clot can dislodge from the body of the occlusion. The distal pores 206 provide a mechanism for preventing the loose fragments from passing distal to the stentriever 100 as the clot and device are removed from the vessel.
A distal engagement section 202 can include a plurality of distal clot cells 208 positioned proximal to the distal membrane 204. The distal clot cells 208 can be part of the frame of the distal engagement section 202. For example, the distal engagement section 202 can be a braided mesh of the materials described above, and the distal clot cells 208 can be the areas between the scaffold of the braided mesh. When the stentriever 100 is removed from the vessel, the distal clot cells 208 can help to grip the clot and prevent the clot from moving distal to the stentriever. The distal clot cells 208 can also provide a mechanism for preventing loose fragments of the clot from passing distal to the stentriever 100 as the clot and device are removed from the vessel.
An intermediate flow channel 402 can include a membrane, similar to the proximal flow membrane 110 described above for the proximal flow channel 108. The intermediate flow channel 402 can direct a flow of aspirate from the second expandable clot engagement section 114 to a position proximal to the second expandable clot engagement section 114. The flow of the aspirate through the intermediate flow channel 402 can be used to localize the suction upon the clot. For example, an intermediate flow channel 402 can allow the aspirate suction to be directed to the second clot inlet 118, further improving the grip on the clot. In some examples, a certain amount of open space can be disposed between the proximal end of the intermediate flow channel 402 and the first clot inlet 106 (as shown in the figure) such that the first clot inlet 106 has room to capture at least a portion of the clot.
The inner channel 404 can include inner channel membranes 406 at positions along the length of the inner channel 404. The inner channel membranes 406 can be made similar materials as those described for the proximal flow membrane 110 above. The inner channel membranes 406 can be positioned at locations on the length of the inner channel 404 to correspond with the one or more clot engagement sections described above. For example, an inner channel membrane 406 can be positioned proximate a second expandable clot engagement section 114 (not shown in the figure) such that aspirate can be directed from the second expandable clot engagement section 114, into the inner channel membrane 406, and proximal in the device. In some examples, an inner channel membrane 406 can be provided proximate the distal engagement section 202 (not shown in the figure) to direct flow from the distal engagement section 202.
In some examples, the inner channel 404 can include a plurality of inner channel pores 408 within the surface of the inner channel 404. The inner channel pores 408 can be openings that allow fluid to flow from an area outside of the inner channel 404 to an area inside the inner channel 404. The inner channel pores 408 can extend from the proximal flow membrane 110 to the end of the inner channel 404; in examples with one or more inner channel membranes 406, the inner channel pores 408 can reside in areas not covered with membrane material. In some examples, the inner channel pores 408 can be cut, etched, drilled, or the like into the surface of the inner channel 404. In other examples, the inner channel pores 408 can be inherent features of the inner channel 404 material. For example, if an inner channel 404 is a braided tube or the like, the inner channel pores 408 can be the area between the braids of the material. The inner channel pores 408 can serve to prevent large clot fragments from entering the inner channel 404, thereby preventing the stentriever 100 from clogging. Clogging of the proximal end of the stentriever 100 could degrade the suction described herein that improves the grip on the clot. It is contemplated that the inner channel pores 408 can have a length and/or diameter (depending on the shape of the particular inner channel pore 408) that is from approximately 200 micrometers to approximately 1.50 mm (e.g., from approximately 200 micrometers to approximately 500 micrometers; from approximately 500 micrometers to approximately 800 micrometers; from approximately 800 micrometers to approximately 1.20 mm; or from approximately 1.20 mm to approximately 1.50 mm). These dimensions can prevent large clot fragments from entering the inner channel 404 and clogging the suction but can also allow small fragments to be aspirated and removed from the area (e.g., through the proximal flow channel 108 and intermediate catheter 300).
In some examples, the distal end of the distal engagement section 202 can, in lieu of distal pores 206 (as shown in
As shown in
As shown in
As shown in
As shown in
Referring to method 1000 as outlined in
The method 1000 illustrated in
The methods 1000 and 1060 as illustrated in
The methods 1000, 1060, and 1100, as illustrated in
As an alternative to the steps provided in method 1200a as outlined in
The descriptions contained herein are examples of embodiments of the invention and are not intended in any way to limit the scope of the invention. As described herein, the invention contemplates many variations and modifications of the stentriever device including using alternative geometries of structural elements, combining shapes and structural elements from various example embodiments, using alternative materials, etc. These modifications would be apparent to those having ordinary skill in the art to which this invention relates and are intended to be within the scope of the claims which follow.
Number | Name | Date | Kind |
---|---|---|---|
4455717 | Gray | Jun 1984 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4612931 | Dormia | Sep 1986 | A |
4727873 | Mobin-Uddin | Mar 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5084065 | David et al. | Jan 1992 | A |
5092839 | Kipperman | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5108419 | Reger et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5217441 | Shichman | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5330482 | Gibbs et al. | Jul 1994 | A |
5383887 | Nadal | Jan 1995 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5499985 | Hein et al. | Mar 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5538515 | Kafry et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant et al. | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5653605 | Woehl et al. | Aug 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark et al. | Feb 1998 | A |
5769871 | Mers Kelly et al. | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5779686 | Sato et al. | Jul 1998 | A |
5779716 | Cano et al. | Jul 1998 | A |
5800519 | Sandock | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel | Sep 1998 | A |
5827304 | Hart | Oct 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5897567 | Ressemann et al. | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911702 | Romley et al. | Jun 1999 | A |
5911725 | Boury | Jun 1999 | A |
5919126 | Armini | Jul 1999 | A |
5931509 | Bartholomew | Aug 1999 | A |
5935139 | Bates | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates et al. | Aug 2000 | A |
6099559 | Nolting | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6143022 | Shull et al. | Nov 2000 | A |
6146404 | Kim et al. | Nov 2000 | A |
6156064 | Chouinard | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6221096 | Aiba et al. | Apr 2001 | B1 |
6231597 | Deem et al. | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6267777 | Bosma et al. | Jul 2001 | B1 |
6290710 | Cryer et al. | Sep 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6325815 | Kusleika et al. | Dec 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6348056 | Bates et al. | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6355057 | DeMarais et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick et al. | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6485497 | Wensel et al. | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael et al. | Nov 2002 | B2 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6511492 | Rosenbluth et al. | Jan 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6530939 | Hopkins et al. | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575996 | Denison et al. | Jun 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592616 | Stack et al. | Jul 2003 | B1 |
6602265 | Dubrul et al. | Aug 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6638245 | Miller et al. | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth et al. | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel et al. | Feb 2004 | B2 |
6692509 | Wensel et al. | Feb 2004 | B2 |
6695858 | Dubrul et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6709465 | Mitchell et al. | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6726703 | Broome et al. | Apr 2004 | B2 |
6730104 | Sepetka et al. | May 2004 | B1 |
6783528 | Vincent-Prestigiacomo | Aug 2004 | B2 |
6783538 | McGuckin, Jr. et al. | Aug 2004 | B2 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer et al. | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6939361 | Kleshinski | Sep 2005 | B1 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6989021 | Bosma et al. | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen et al. | Feb 2006 | B2 |
7004956 | Palmer et al. | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto et al. | May 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7052500 | Bashiri et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose et al. | Jun 2006 | B2 |
7083633 | Morrill et al. | Aug 2006 | B2 |
7083822 | Brightbill | Aug 2006 | B2 |
7094249 | Broome et al. | Aug 2006 | B1 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101380 | Khachin et al. | Sep 2006 | B2 |
7172614 | Boyle et al. | Feb 2007 | B2 |
7175655 | Molaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7185922 | Takayanagi et al. | Mar 2007 | B2 |
7220271 | Clubb et al. | May 2007 | B2 |
7226464 | Garner et al. | Jun 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7241304 | Boyle et al. | Jul 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7300458 | Henkes et al. | Nov 2007 | B2 |
7306618 | Demond et al. | Dec 2007 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Clubb et al. | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins et al. | Aug 2008 | B2 |
7425215 | Boyle et al. | Sep 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka et al. | May 2009 | B2 |
7556636 | Mazzocchi et al. | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Linder et al. | Sep 2009 | B2 |
7604649 | McGuckin, Jr. et al. | Oct 2009 | B2 |
7604650 | Bergheim | Oct 2009 | B2 |
7618434 | Santra et al. | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678123 | Chanduszko | Mar 2010 | B2 |
7691121 | Rosenbluth et al. | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder et al. | May 2010 | B2 |
7717929 | Fallman | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7758606 | Streeter et al. | Jul 2010 | B2 |
7758611 | Kato | Jul 2010 | B2 |
7766934 | Pal et al. | Aug 2010 | B2 |
7771452 | Pal et al. | Aug 2010 | B2 |
7780694 | Palmer et al. | Aug 2010 | B2 |
7780700 | Frazier et al. | Aug 2010 | B2 |
7811305 | Balgobin et al. | Oct 2010 | B2 |
7815659 | Conlon et al. | Oct 2010 | B2 |
7819893 | Brady et al. | Oct 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7833240 | Okushi et al. | Nov 2010 | B2 |
7842053 | Chanduszko et al. | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7846176 | Gilson et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7883516 | Huang et al. | Feb 2011 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8048151 | OBrien et al. | Nov 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8057507 | Horan et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Garrison et al. | Feb 2012 | B2 |
8118856 | Schreck et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137376 | Clubb et al. | Mar 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8262689 | Schneiderman et al. | Sep 2012 | B2 |
8282668 | McGuckin, Jr. et al. | Oct 2012 | B2 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
RE43882 | Hopkins et al. | Dec 2012 | E |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8357180 | Feller, III et al. | Jan 2013 | B2 |
8357893 | Xu et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8361110 | Chanduszko | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8414482 | Belson | Apr 2013 | B2 |
8414543 | McGuckin, Jr. et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8512352 | Martin | Aug 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8545526 | Martin et al. | Oct 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osborne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8690907 | Janardhan et al. | Apr 2014 | B1 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702704 | Shelton, IV et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8777976 | Brady et al. | Jul 2014 | B2 |
8777979 | Shrivastava et al. | Jul 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Martin et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8852205 | Brady et al. | Oct 2014 | B2 |
8870941 | Evans et al. | Oct 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8920358 | Levine et al. | Dec 2014 | B2 |
8939991 | Krolik et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945160 | Krolik et al. | Feb 2015 | B2 |
8945169 | Pal | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8956399 | Cam et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9011481 | Aggerholm et al. | Apr 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9095342 | Becking et al. | Aug 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161758 | Figulla et al. | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9211132 | Bowman | Dec 2015 | B2 |
9232992 | Heidner | Jan 2016 | B2 |
9254371 | Martin et al. | Feb 2016 | B2 |
9301769 | Brady et al. | Apr 2016 | B2 |
9332999 | Ray et al. | May 2016 | B2 |
9402707 | Brady et al. | Aug 2016 | B2 |
9445829 | Brady et al. | Sep 2016 | B2 |
9456834 | Folk | Oct 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9532873 | Kelley | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539011 | Chen et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9539382 | Nelson | Jan 2017 | B2 |
9549830 | Bruszewski et al. | Jan 2017 | B2 |
9554805 | Tompkins et al. | Jan 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9572982 | Burnes et al. | Feb 2017 | B2 |
9579104 | Beckham et al. | Feb 2017 | B2 |
9579484 | Barnell | Feb 2017 | B2 |
9585642 | Dinsmoor et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Apr 2017 | B2 |
9615951 | Bennett et al. | Apr 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9636115 | Henry et al. | May 2017 | B2 |
9636439 | Chu et al. | May 2017 | B2 |
9642639 | Brady et al. | May 2017 | B2 |
9642675 | Werneth et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655645 | Staunton | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662238 | Dwork et al. | May 2017 | B2 |
9662425 | Lilja et al. | May 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9675477 | Thompson | Jun 2017 | B2 |
9675782 | Connolly | Jun 2017 | B2 |
9676022 | Ensign | Jun 2017 | B2 |
9692557 | Murphy | Jun 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9700262 | Janik et al. | Jul 2017 | B2 |
9700399 | Acosta-Acevedo | Jul 2017 | B2 |
9717421 | Griswold et al. | Aug 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9717502 | Teoh et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724526 | Strother et al. | Aug 2017 | B2 |
9750565 | Bloom et al. | Sep 2017 | B2 |
9757260 | Greenan | Sep 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman | Sep 2017 | B2 |
9770577 | Li | Sep 2017 | B2 |
9775621 | Tompkins et al. | Oct 2017 | B2 |
9775706 | Peterson | Oct 2017 | B2 |
9775732 | Khenansho | Oct 2017 | B2 |
9788800 | Mayoras, Jr. | Oct 2017 | B2 |
9795391 | Saatchi et al. | Oct 2017 | B2 |
9801980 | Karino et al. | Oct 2017 | B2 |
9808599 | Bowman | Nov 2017 | B2 |
9833252 | Sepetka | Dec 2017 | B2 |
9833304 | Horan et al. | Dec 2017 | B2 |
9833604 | Lam | Dec 2017 | B2 |
9833625 | Waldhauser et al. | Dec 2017 | B2 |
9901434 | Hoffman | Feb 2018 | B2 |
9918720 | Marchand et al. | Mar 2018 | B2 |
10016206 | Yang | Jul 2018 | B1 |
10070878 | Ma | Sep 2018 | B2 |
10098651 | Marchand et al. | Oct 2018 | B2 |
10201360 | Vale et al. | Feb 2019 | B2 |
10231751 | Sos | Mar 2019 | B2 |
10292723 | Brady et al. | May 2019 | B2 |
10299811 | Brady et al. | May 2019 | B2 |
10363054 | Vale et al. | Jul 2019 | B2 |
10376274 | Farin et al. | Aug 2019 | B2 |
10390850 | Vale et al. | Aug 2019 | B2 |
10524811 | Marchand et al. | Jan 2020 | B2 |
10617435 | Vale et al. | Apr 2020 | B2 |
10722257 | Skillrud et al. | Jul 2020 | B2 |
20010001315 | Bates et al. | May 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010049554 | Ruiz et al. | Dec 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020016609 | Wensel et al. | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020042627 | Brady et al. | Apr 2002 | A1 |
20020049468 | Streeter et al. | Apr 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020058911 | Gilson et al. | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020138094 | Borillo et al. | Sep 2002 | A1 |
20020143349 | Gifford, III et al. | Oct 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond et al. | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020188276 | Evans et al. | Dec 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193824 | Boylan et al. | Dec 2002 | A1 |
20020198588 | Armstrong et al. | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030004540 | Linder et al. | Jan 2003 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030009146 | Muni et al. | Jan 2003 | A1 |
20030009191 | Wensel et al. | Jan 2003 | A1 |
20030038447 | Cantele | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin et al. | Mar 2003 | A1 |
20030114879 | Euteneuer et al. | Jun 2003 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030144688 | Brady et al. | Jul 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung et al. | Aug 2003 | A1 |
20030163064 | Vrba et al. | Aug 2003 | A1 |
20030163158 | White | Aug 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030171771 | Anderson et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030195537 | Dubrul et al. | Oct 2003 | A1 |
20030195554 | Shen et al. | Oct 2003 | A1 |
20030199917 | Knudson et al. | Oct 2003 | A1 |
20030204202 | Palmer et al. | Oct 2003 | A1 |
20030208224 | Broome | Nov 2003 | A1 |
20030212430 | Bose et al. | Nov 2003 | A1 |
20030236533 | Wilson et al. | Dec 2003 | A1 |
20040064179 | Linder et al. | Apr 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040079429 | Miller et al. | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040082967 | Broome et al. | Apr 2004 | A1 |
20040088001 | Bosma et al. | May 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040098050 | Foerster et al. | May 2004 | A1 |
20040133231 | Maitland et al. | Jul 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040153117 | Clubb et al. | Aug 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20040215318 | Kwitkin | Oct 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20050033348 | Sepetka et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050049619 | Sepetka et al. | Mar 2005 | A1 |
20050049669 | Jones et al. | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka et al. | Mar 2005 | A1 |
20050085849 | Sepetka et al. | Apr 2005 | A1 |
20050090779 | Osypka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050125024 | Sepetka et al. | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050216030 | Sepetka et al. | Sep 2005 | A1 |
20050216050 | Sepetka et al. | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20050251206 | Maahs et al. | Nov 2005 | A1 |
20050251209 | Saadat et al. | Nov 2005 | A1 |
20050267491 | Kellett et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20050288686 | Sepetka et al. | Dec 2005 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060020285 | Niermann | Jan 2006 | A1 |
20060020286 | Niermann | Jan 2006 | A1 |
20060030877 | Martinez et al. | Feb 2006 | A1 |
20060041228 | Vo et al. | Feb 2006 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060064151 | Guterman | Mar 2006 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060074477 | Berthiaume et al. | Apr 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka et al. | Aug 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk et al. | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241677 | Johnson et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20060293706 | Shimon | Dec 2006 | A1 |
20070010857 | Sugimoto et al. | Jan 2007 | A1 |
20070032879 | Levine et al. | Feb 2007 | A1 |
20070088382 | Bei et al. | Apr 2007 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070100348 | Cauthen, III et al. | May 2007 | A1 |
20070118173 | Magnuson et al. | May 2007 | A1 |
20070149997 | Muller | Jun 2007 | A1 |
20070156170 | Hancock et al. | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070179527 | Eskuri et al. | Aug 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski et al. | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070208371 | French et al. | Sep 2007 | A1 |
20070225749 | Martin et al. | Sep 2007 | A1 |
20070233175 | Zaver et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288054 | Tanaka et al. | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080077227 | Ouellette et al. | Mar 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney et al. | Apr 2008 | A1 |
20080097386 | Osypka | Apr 2008 | A1 |
20080109031 | Sepetka et al. | May 2008 | A1 |
20080109032 | Sepetka et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080125798 | Osborne et al. | May 2008 | A1 |
20080177296 | Sepetka et al. | Jul 2008 | A1 |
20080178890 | Townsend et al. | Jul 2008 | A1 |
20080183197 | Sepetka et al. | Jul 2008 | A1 |
20080183198 | Sepetka et al. | Jul 2008 | A1 |
20080183205 | Sepetka et al. | Jul 2008 | A1 |
20080188876 | Sepetka et al. | Aug 2008 | A1 |
20080188885 | Sepetka et al. | Aug 2008 | A1 |
20080188887 | Batiste | Aug 2008 | A1 |
20080200946 | Braun et al. | Aug 2008 | A1 |
20080200947 | Kusleika et al. | Aug 2008 | A1 |
20080215077 | Sepetka et al. | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka et al. | Sep 2008 | A1 |
20080243170 | Jenson et al. | Oct 2008 | A1 |
20080255596 | Jenson et al. | Oct 2008 | A1 |
20080262410 | Jenson et al. | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080269871 | Eli | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080281350 | Sepetka | Nov 2008 | A1 |
20080312681 | Ansel et al. | Dec 2008 | A1 |
20090005858 | Young et al. | Jan 2009 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090030443 | Buser et al. | Jan 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090069828 | Martin et al. | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090088793 | Bagaoisan et al. | Apr 2009 | A1 |
20090088795 | Cahill | Apr 2009 | A1 |
20090105722 | Fulkerson et al. | Apr 2009 | A1 |
20090105737 | Fulkerson et al. | Apr 2009 | A1 |
20090105747 | Chanduszko et al. | Apr 2009 | A1 |
20090149881 | Vale et al. | Jun 2009 | A1 |
20090163851 | Holloway et al. | Jun 2009 | A1 |
20090177206 | Lozier et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20090299403 | Chanduszko et al. | Dec 2009 | A1 |
20090306702 | Miloslavski et al. | Dec 2009 | A1 |
20090326636 | Hashimoto et al. | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100076482 | Shu et al. | Mar 2010 | A1 |
20100087850 | Razack | Apr 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100125326 | Kalstad et al. | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100268264 | Bonnette et al. | Oct 2010 | A1 |
20100268265 | Krolik et al. | Oct 2010 | A1 |
20100274277 | Eaton | Oct 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324649 | Mattsson | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110009950 | Grandfield et al. | Jan 2011 | A1 |
20110015718 | Schreck | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110040319 | Fulton, III | Feb 2011 | A1 |
20110054504 | Porter | Mar 2011 | A1 |
20110054514 | Arcand et al. | Mar 2011 | A1 |
20110054516 | Keegan et al. | Mar 2011 | A1 |
20110060212 | Slee et al. | Mar 2011 | A1 |
20110060359 | Hannes et al. | Mar 2011 | A1 |
20110106137 | Shimon | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110184456 | Grandfield et al. | Jul 2011 | A1 |
20110196414 | Porter | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110208233 | McGuckin, Jr. et al. | Aug 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213393 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110224707 | Miloslavski et al. | Sep 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110319917 | Ferrera et al. | Dec 2011 | A1 |
20120022572 | Braun | Jan 2012 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | di Palma et al. | Mar 2012 | A1 |
20120065660 | Ferrera et al. | Mar 2012 | A1 |
20120083823 | Shrivastava et al. | Apr 2012 | A1 |
20120083868 | Shrivastava et al. | Apr 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120123466 | Porter et al. | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120209312 | Aggerholm et al. | Aug 2012 | A1 |
20120215250 | Grandfield et al. | Aug 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20120316600 | Ferrera et al. | Dec 2012 | A1 |
20120330350 | Jones et al. | Dec 2012 | A1 |
20130030460 | Marks et al. | Jan 2013 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130131614 | Hassan et al. | May 2013 | A1 |
20130144311 | Fung et al. | Jun 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130325051 | Martin et al. | Dec 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130345739 | Brady | Dec 2013 | A1 |
20140005712 | Martin | Jan 2014 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140134654 | Rudel et al. | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140142598 | Fulton, III | May 2014 | A1 |
20140180122 | Stigall et al. | Jun 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140180397 | Gerberding et al. | Jun 2014 | A1 |
20140194911 | Johnson et al. | Jul 2014 | A1 |
20140194919 | Losordo et al. | Jul 2014 | A1 |
20140200607 | Sepetka et al. | Jul 2014 | A1 |
20140200608 | Brady et al. | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140243881 | Lees et al. | Aug 2014 | A1 |
20140257362 | Eidenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140303667 | Cox et al. | Oct 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Fekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150032144 | Holloway | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150112376 | Molaei | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150150672 | Ma | Jun 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150224133 | Ohri et al. | Aug 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150272716 | Pinchuk et al. | Oct 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm | Nov 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150366650 | Zi et al. | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160045298 | Thinnes, Jr. et al. | Feb 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160100928 | Lees et al. | Apr 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
20160256180 | Vale et al. | Sep 2016 | A1 |
20160303381 | Pierce et al. | Oct 2016 | A1 |
20160317168 | Brady et al. | Nov 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007265 | Guo et al. | Jan 2017 | A1 |
20170020542 | Martin et al. | Jan 2017 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170020700 | Bienvenu | Jan 2017 | A1 |
20170027640 | Kunis et al. | Feb 2017 | A1 |
20170027692 | Bonhoeffer | Feb 2017 | A1 |
20170027725 | Argentine | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035567 | Duffy | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170049596 | Schabert | Feb 2017 | A1 |
20170056061 | Ogle et al. | Mar 2017 | A1 |
20170071614 | Vale et al. | Mar 2017 | A1 |
20170071737 | Kelley | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079671 | Morero | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079766 | Wang | Mar 2017 | A1 |
20170079767 | Leon-Yip | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170086851 | Wallace | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170086863 | Brady et al. | Mar 2017 | A1 |
20170086996 | Peterson et al. | Mar 2017 | A1 |
20170095259 | Tompkins et al. | Apr 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100141 | Morero et al. | Apr 2017 | A1 |
20170100143 | Granfield | Apr 2017 | A1 |
20170100183 | Iaizzo | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170112515 | Brady et al. | Apr 2017 | A1 |
20170112647 | Sachar et al. | Apr 2017 | A1 |
20170113023 | Steingisser et al. | Apr 2017 | A1 |
20170119409 | Ma | May 2017 | A1 |
20170143465 | Ulm, III | May 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170150979 | John | Jun 2017 | A1 |
20170151032 | Loisel | Jun 2017 | A1 |
20170165062 | Rothstein | Jun 2017 | A1 |
20170165065 | Rothstein | Jun 2017 | A1 |
20170165454 | Tuohy | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170172772 | Khenansho | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224467 | Piccagli et al. | Aug 2017 | A1 |
20170224511 | Dwork et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170231749 | Perkins et al. | Aug 2017 | A1 |
20170252064 | Staunton | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281331 | Perkins et al. | Oct 2017 | A1 |
20170281344 | Costello | Oct 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170281912 | Melder | Oct 2017 | A1 |
20170290593 | Cruise et al. | Oct 2017 | A1 |
20170290654 | Sethna | Oct 2017 | A1 |
20170296324 | Argentine | Oct 2017 | A1 |
20170296325 | Marrocco et al. | Oct 2017 | A1 |
20170303939 | Greenhalgh | Oct 2017 | A1 |
20170303942 | Greenhalgh et al. | Oct 2017 | A1 |
20170303947 | Greenhalgh | Oct 2017 | A1 |
20170303948 | Wallace et al. | Oct 2017 | A1 |
20170304041 | Argentine | Oct 2017 | A1 |
20170304097 | Corwin et al. | Oct 2017 | A1 |
20170304595 | Nagasrinivasa | Oct 2017 | A1 |
20170312109 | Le | Nov 2017 | A1 |
20170312484 | Shipley et al. | Nov 2017 | A1 |
20170316561 | Helm et al. | Nov 2017 | A1 |
20170319826 | Bowman | Nov 2017 | A1 |
20170333228 | Orth et al. | Nov 2017 | A1 |
20170333236 | Greenan | Nov 2017 | A1 |
20170333678 | Bowman | Nov 2017 | A1 |
20170340383 | Bloom et al. | Nov 2017 | A1 |
20170348014 | Wallace | Dec 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20180263650 | Iwanami et al. | Sep 2018 | A1 |
20180325537 | Shamay et al. | Nov 2018 | A1 |
20180326024 | Prochazka et al. | Nov 2018 | A1 |
20180344338 | Brady et al. | Dec 2018 | A1 |
20190000492 | Casey et al. | Jan 2019 | A1 |
20190015061 | Liebeskind et al. | Jan 2019 | A1 |
20190167284 | Friedman et al. | Jun 2019 | A1 |
20190239907 | Brady et al. | Aug 2019 | A1 |
20190292273 | Hanotin et al. | Sep 2019 | A1 |
20190374239 | Martin et al. | Dec 2019 | A1 |
20190380723 | Grandfield et al. | Dec 2019 | A1 |
20190388097 | Girdhar et al. | Dec 2019 | A1 |
20200009150 | Chamorro Sanchez | Jan 2020 | A1 |
20200100804 | Casey et al. | Apr 2020 | A1 |
20200297364 | Choe et al. | Sep 2020 | A1 |
Number | Date | Country |
---|---|---|
2557083 | Jun 2003 | CN |
101172051 | May 2008 | CN |
102307613 | Jan 2012 | CN |
102596098 | Jul 2012 | CN |
103764049 | Apr 2014 | CN |
104042304 | Sep 2014 | CN |
105208950 | Dec 2015 | CN |
105662532 | Jun 2016 | CN |
205359559 | Jul 2016 | CN |
107530090 | Jan 2018 | CN |
208582467 | Mar 2019 | CN |
202009001951 | Mar 2010 | DE |
102009056450 | Jun 2011 | DE |
102010010849 | Sep 2011 | DE |
102010014778 | Oct 2011 | DE |
102010024085 | Dec 2011 | DE |
102011014586 | Sep 2012 | DE |
2301450 | Mar 2011 | EP |
1153581 | Nov 2011 | EP |
2438891 | Apr 2012 | EP |
2628455 | Aug 2013 | EP |
3156004 | Apr 2017 | EP |
2427554 | Jan 2007 | GB |
2494820 | Mar 2013 | GB |
09-19438 | Jan 1997 | JP |
2014-511223 | May 2014 | JP |
2014-525796 | Oct 2014 | JP |
2016-513505 | May 2016 | JP |
2019-526365 | Sep 2019 | JP |
WO 9424926 | Nov 1994 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9738631 | Oct 1997 | WO |
WO 9920335 | Apr 1999 | WO |
WO 9956801 | Nov 1999 | WO |
WO 9960933 | Dec 1999 | WO |
WO 0121077 | Mar 2001 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0211627 | Feb 2002 | WO |
WO 0243616 | Jun 2002 | WO |
WO 02070061 | Sep 2002 | WO |
WO 02094111 | Nov 2002 | WO |
WO 03002006 | Jan 2003 | WO |
WO 03030751 | Apr 2003 | WO |
WO 03051448 | Jun 2003 | WO |
WO 2004028571 | Apr 2004 | WO |
WO 2004056275 | Jul 2004 | WO |
WO 2005000130 | Jan 2005 | WO |
WO 2005027779 | Mar 2005 | WO |
WO 2006021407 | Mar 2006 | WO |
WO 2006031410 | Mar 2006 | WO |
WO 2006107641 | Oct 2006 | WO |
WO 2006135823 | Dec 2006 | WO |
WO 2007054307 | May 2007 | WO |
WO 2007068424 | Jun 2007 | WO |
WO 2008034615 | Mar 2008 | WO |
WO 2008051431 | May 2008 | WO |
WO 2008131116 | Oct 2008 | WO |
WO 2008135823 | Nov 2008 | WO |
WO 2009031338 | Mar 2009 | WO |
WO 2009076482 | Jun 2009 | WO |
WO 2009086482 | Jul 2009 | WO |
WO 2009105710 | Aug 2009 | WO |
WO 2010010545 | Jan 2010 | WO |
WO 2010046897 | Apr 2010 | WO |
WO 2010075565 | Jul 2010 | WO |
WO 2010102307 | Sep 2010 | WO |
WO 2010146581 | Dec 2010 | WO |
WO 2011013556 | Feb 2011 | WO |
WO 2011066961 | Jun 2011 | WO |
WO 2011082319 | Jul 2011 | WO |
WO 2011095352 | Aug 2011 | WO |
WO 2011106426 | Sep 2011 | WO |
WO 2011110316 | Sep 2011 | WO |
WO 2011135556 | Nov 2011 | WO |
WO 2012052982 | Apr 2012 | WO |
WO 2012064726 | May 2012 | WO |
WO 2012081020 | Jun 2012 | WO |
WO 2012110619 | Aug 2012 | WO |
WO 2012120490 | Sep 2012 | WO |
WO 2012156924 | Nov 2012 | WO |
WO 2013016435 | Jan 2013 | WO |
WO 2013072777 | May 2013 | WO |
WO 2013105099 | Jul 2013 | WO |
WO 2013109756 | Jul 2013 | WO |
WO 2013187927 | Dec 2013 | WO |
WO 2014047650 | Mar 2014 | WO |
WO 2014081892 | May 2014 | WO |
WO 2014139845 | Sep 2014 | WO |
WO 2014169266 | Oct 2014 | WO |
WO 2014178198 | Nov 2014 | WO |
WO 2015061365 | Apr 2015 | WO |
WO 2015103547 | Jul 2015 | WO |
WO 2015134625 | Sep 2015 | WO |
WO 2015179324 | Nov 2015 | WO |
WO 2015189354 | Dec 2015 | WO |
WO 2016010995 | Jan 2016 | WO |
WO 2016089451 | Jun 2016 | WO |
WO 2017089424 | Jun 2017 | WO |
WO 2017103686 | Jun 2017 | WO |
WO 2017161204 | Sep 2017 | WO |
WO 2020039082 | Feb 2020 | WO |
WO 2021113302 | Jun 2021 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn) |
Number | Date | Country | |
---|---|---|---|
20210161544 A1 | Jun 2021 | US |